Rodgers.Manual de hematología clínica_5ed

384

BETHESDA. MANUAL DE HEMATOLOGÍA CLÍNICA

46. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies. Lupus . 2011;20:206‐218. 47. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syn drome in adults. Ann Rheum Dis . 2019;78(10):1296‐1304. doi:10.1136/annrheumdis-2019-215213 48. Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglo binuria (PNH). Blood . 2003;102:3587‐3591. 49. van Bijnen ST, van Heerde WL, Muus P. Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria. J Thromb Haemost . 2012;10(1):1‐10. doi:10.1111/j.1538-7836.2011.04562.x 50. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood . 2007;110:4123‐4128. 51. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv . 2019;3(23):3898‐3944. doi:10.1182/bloodadvances.2019000975 52. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol . 2020;38(5):496‐520. doi:10.1200/JCO.19.01461 53. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood . 2002;117:47. 54. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3. Erratum in: Lancet . 2020;395(10229):1038. 55. Thomas MR, Scully M. Clinical features of thrombosis and bleeding in COVID-19. Blood . 2022;140(3):184‐195. doi:10.1182/blood.2021012247 56. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine . 2020;29:100639. doi:10.1016/j.eclinm.2020.100639 57. Henrina J, Putra ICS, Cahyadi I, et al. Clinical characteristics and outcomes of venous thromboembolism in patients hospitalized for COVID-19: systematic review and meta-analysis . Thrombosis Update . 2021;2:100037. ISSN 2666-5727. https://doi.org/10.1016/j.tru.2021.100037 58. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coro navirus disease 2019: CHEST Guideline and Expert Panel Report. Chest . 2020;158(3):1143‐1163. doi:10.1016/j. chest.2020.05.559 59. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med . 2020;383(2):120‐128. doi:10.1056/NEJMoa2015432 60. Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv . 2022;6(17):4915-4923. doi:10.1182/bloodadvances.2022007561. Update in: doi:10.1182/ bloodadvances.2020003763 61. Cuker A, Tseng EK, Schünemann HJ, et al. American Society of Hematology living guidelines on the use of anticoagula tion for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Adv . 2022;6(17):4975-4982. doi:10.1182/bloodadvances.2022007940. Update in: doi:10.1182/bloodad vances.2020003763 62. Jiménez D, García-Sanchez A, Rali P, et al. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest . 2021;159(3):1182‐1196. doi:10.1016/j.chest.2020.11.005 63. Lim MY, Moll S. Thrombophilia. Vasc Med . 2015;20(2):193‐196. doi:10.1177/1358863X15575769 64. Kamphuisen PW, Eikenboom JCJ, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol . 2001;21:731‐738. 65. Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost . 2000;83:1‐2. 66. Lowe GDO, Woodward M, Vessey MP, et al. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45–64 years: relationships to hormone replacement therapy. Thromb Haemost . 2000;83:530‐535. 67. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet . 1996;348:977‐980. 68. Meijers JCM, Tekelenburg WLH, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous throm bosis. N Engl J Med . 2000;342:696‐701. 69. Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis . 2015;39(3):367‐378. doi:10.1007/s11239-015-1197-3 70. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implica tions for venous thromboembolism screening. JAMA . 1997;277:1305‐1307. 71. Williamson D, Brown K, Luddington R, et al. Factor V Cambridge: a new mutation (Arg306 → Thr) associated with resis tance to activated protein C. Blood . 1998;91:1140‐1144. 72. Chan WP, Lee CK, Kwong YL, et al. A novel mutation of Arg 306 of factor V gene in Hong Kong Chinese. Blood . 1998;91:1135‐1139.

Copyright © 2025 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.